CardoMax, LLC – Trademark Portfolio

Entity Type: 16

CardoMax, LLC holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 32 (Light Beverages) — 5 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include CX, AAT, CARDOMAX, CX CARDOMAX, and ACCELERATED ABSORPTION TECHNOLOGY. The owner is based in Virginia Beach, VA.

Ste 110A

544 Central Dr

Virginia Beach, VA 23454

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

CardoMax, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

32
Light Beverages (5 filings)

Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does CardoMax, LLC have?

CardoMax, LLC has 5 U.S. trademarks filed with the USPTO. Of these, 5 registered.

What trademark classes does CardoMax, LLC file in?

CardoMax, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 32 (Light Beverages), Class 5 (Pharmaceuticals). Class 32 covers beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages.

What are CardoMax, LLC's most well-known trademarks?

CardoMax, LLC's registered trademark portfolio includes well-known marks such as CX, AAT, CARDOMAX, CX CARDOMAX, and ACCELERATED ABSORPTION TECHNOLOGY. These are among 5 currently registered trademarks in the portfolio.

What is CardoMax, LLC's trademark registration success rate?

CardoMax, LLC has a 100% trademark registration rate, with 5 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.